HLX26 vs Relatlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: LAG-3 · full Non-Small Cell Lung Cancer pipeline

HLX26

Developed by Shanghai Henlius Biotech

Phase 2 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Relatlimab

Marketed by Bristol-Myers Squibb and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT04623775 · Phase 2 · completed

The trial was randomized, triple-blind, and active-controlled, with 468 participants, and its primary efficacy endpoint was a clinical tumor-response measure. However, neither the Part 2 objective response comparison nor the Part 1 primary safety comparison was statistically significant, so the results provide well-designed but inconclusive evidence for relatlimab.

Next expected readout: January 2027 · NCT05176483 (registry estimate)

Reported efficacy

TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1 (from first dose to 12 weeks after first dose); ORR Per RECISTS v1.1 by BICR in Part 2 (Approximately 14.8 Months): Part 2 objective response rate by BICR (RECIST 1.1): nivolumab + relatlimab + chemotherapy 50.6% (90% CI 43.8 to 57.4, n=158) vs nivolumab + chemotherapy 43.0% (90% CI 36.2 to 50.1, n=151); odds ratio 1.39 (90% CI 0.94 to 2.05). The Part 1 co-primary (TRAEs leading to discontinuation within 12 weeks) compares two relatlimab regimens: 5.6% vs 12.1% (CT.gov posted results). (missed)

Result source: NCT04623775

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHLX26Relatlimab
PFS, median—Not reported—Trial running · NCT06561386
OS, median—Not reported—Trial running · NCT06561386
ORR—Not reported50.6% vs 43%vs Nivolumab + Chemotherapywk 64 · n 158NCT04623775
Duration of response, median—Not reported8.4 vs 7.1vs Nivolumab + Chemotherapyn 158NCT04623775

PFS, median

HLX26
—Not reported
Relatlimab
—Trial running · NCT06561386

OS, median

HLX26
—Not reported
Relatlimab
—Trial running · NCT06561386

ORR

HLX26
—Not reported
Relatlimab
50.6% vs 43%vs Nivolumab + Chemotherapywk 64 · n 158NCT04623775

Duration of response, median

HLX26
—Not reported
Relatlimab
8.4 vs 7.1vs Nivolumab + Chemotherapyn 158NCT04623775
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HLX26: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HLX26: 0 of 4 rows · Relatlimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRelatlimab
Dropout rate
2.5%Part 1: Treatment Aa
NCT04623775 · Phase 2 · combination
show 1 more result
0%Part 2: Treatment C
NCT04623775 · Phase 2 · combination
Discontinued due to AEs
—Part 1: Treatment Aa
NCT04623775 · Phase 2 · combination
show 1 more result
—Part 2: Treatment C
NCT04623775 · Phase 2 · combination
Serious AEs
59.7%Part 1: Treatment Aa
NCT04623775 · Phase 2 · combination
show 1 more result
65.2%Part 2: Treatment C
NCT04623775 · Phase 2 · combination
Most frequent reported AEs
a
anaemia 66.2%
fatigue 42.9%
nausea 42.9%
NCT04623775 · Phase 2 · combination
show 1 more result
anaemia 69%
nausea 34.8%
thrombocytopenia 29.7%
NCT04623775 · Phase 2 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Relatlimab

ORR 50.6% (n=158) vs 43% (n=151) Nivolumab + Chemotherapy @ 64wk
responder rate · % of participants
NCT04623775 · Phase 2 · combination
Duration of Response 8.41 vs 7.1 Nivolumab + Chemotherapy months
time to event · months
NCT04623775 · Phase 2 · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX26's landscape · Relatlimab's landscape